Orphan Drug Development – What are the Real Costs?

Keytruda, a case study for the improved regulatory environment in China

Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma

Planning for Competition in Launch Strategy

Orphan Disease Drug Sales – How Much Opportunity is There by Region?

SHIFTING TIDES IN PHARMA DEALMAKING

Stakeholder Engagement Strategies in Launch Planning

The Year That Was: Oncology Edition

Highlights from AAO 2018: Changes in the Management of Retinal Conditions on the Horizon

Drug Launch Performance

Major Themes from Meeting on the Mesa 2018

The Medicines Optimisation Program in England

OCTANe’s Annual OTS 2018 Fuels Excitement in Novel Technologies in Ophthalmology

Realizing the Power of Clinical and Consumer Genomics: Ethics, Business Models, and Regulatory Hurdles

Commercial and Developmental Innovation: What Can We Learn from Gene Therapies?

Early Access Programs in Europe: Differences and Opportunities in Germany, France and the UK

Genomics, will the cards stack up?

Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK

PCSK9 Inhibitors’ Battle for Reimbursement: Germany’s Decision and Implications in Other Countries

Rare Disease Prevalence and Orphan Drug Pricing in Europe

Health Advances Blog

Category: BioPharma

Orphan Drug Development – What are the Real Costs?

Keytruda, a case study for the improved regulatory environment in China

Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma

Planning for Competition in Launch Strategy

Orphan Disease Drug Sales – How Much Opportunity is There by Region?

SHIFTING TIDES IN PHARMA DEALMAKING

Stakeholder Engagement Strategies in Launch Planning

The Year That Was: Oncology Edition

Highlights from AAO 2018: Changes in the Management of Retinal Conditions on the Horizon

Drug Launch Performance

Major Themes from Meeting on the Mesa 2018

The Medicines Optimisation Program in England

OCTANe’s Annual OTS 2018 Fuels Excitement in Novel Technologies in Ophthalmology

Realizing the Power of Clinical and Consumer Genomics: Ethics, Business Models, and Regulatory Hurdles

Commercial and Developmental Innovation: What Can We Learn from Gene Therapies?

Early Access Programs in Europe: Differences and Opportunities in Germany, France and the UK

Genomics, will the cards stack up?

Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK

PCSK9 Inhibitors’ Battle for Reimbursement: Germany’s Decision and Implications in Other Countries

Rare Disease Prevalence and Orphan Drug Pricing in Europe